Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with...

Area of Science:

• Regenerative Medicine
• Cell Therapy
• Musculoskeletal Disorders

Background:

• Duchenne Muscular Dystrophy (DMD) is a severe, progressive, and lethal X-linked muscle wasting disease with no current cure.
• Current treatments for DMD focus on managing symptoms and do not address the underlying genetic defect.

Purpose of the Study:

• To assess the safety and efficacy of a novel Dystrophin Expressing Chimeric (DEC) cell therapy in the first human patients with DMD.
• To evaluate functional outcomes and potential therapeutic benefits of DEC01 in DMD patients.

Main Methods:

• A first-in-human study involving systemic-intraosseous administration of DEC01 cell therapy to three DMD patients.
• Safety was monitored for adverse events (AE) and serious adverse events (SAE).
• Efficacy was assessed using functional tests (6-Minute Walk Test, North Star Ambulatory Assessment), muscle strength, fatigue resistance, and Electromyography (EMG) parameters.

Main Results:

• No study-related adverse events (AE) or serious adverse events (SAE) were observed up to 14 months post-administration.
• Ambulatory patients demonstrated improvements in functional tests (6MWT, NSAA).
• Both ambulatory and non-ambulatory patients showed improvements in PUL, strength, and fatigue resistance, correlating with enhanced EMG parameters.

Conclusions:

• DEC01 cell therapy is safe and well-tolerated in DMD patients.
• The therapy demonstrated potential for functional improvement in muscle strength and endurance in DMD patients.
• DEC01 therapy offers a universal, non-viral vector approach that does not require immunosuppression and can be potentially readministered.